What is the efficacy of calcidiol (25-hydroxyvitamin D) in the treatment of organ transplantation-related osteoporosis?

Updated: Jul 02, 2020
  • Author: Carmel M Fratianni, MD, FACE; Chief Editor: George T Griffing, MD  more...
  • Print


In an uncontrolled 12-month study in 77 renal transplant recipients, Talalaj et al found that BMD remained stable at the LS spine (–0.2%) or modestly increased at the femur neck (1.3%) in subjects who received calcidiol 40 mcg with calcium 3 g daily. A significant decrease in vertebral deformities was notable in the calcidiol group. [93] In the untreated group, BMD significantly decreased, by 7.1% at the LS spine and 5.5% at the femur neck.

Garcia-Delgado et al reported that randomization immediately following cardiac transplant to 32,000 IU per week of oral calcidiol for 18 months increased LS spine BMD, whereas etidronate or nasal calcitonin was associated with a decrease in LS spine BMD. [94]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!